(Reuters) - Peregrine Pharmaceuticals Inc said revised results from a mid-stage study of its experimental drug bavituximab showed that lung cancer patients survived about 4.4 months longer on the drug than with chemotherapy alone. Peregrine's shares jumped 7 percent to $1.97 in premarket trading on Tuesday. Patients survived for a median of 11.7 months when given bavituximab along with chemotherapy, compared with 7.3 months when on chemotherapy alone, the company said. ...
Read the full article...
(From Yahoo Diseases)
Peregrine reports positive results from revised lung cancer trial data (Yahoo)
Linear Mode
